Lymphoma
No cardiac effects from topical hypericin in patients with mycosis fungoides
Topical hypericin showed efficacy in treating mycosis fungoides without significant skin absorption or significant cardiac changes, according to a study.
FDA approves Breyanzi CAR-T for follicular lymphoma
The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of adults with relapsed or refractory follicular lymphoma who received at least two prior lines of systemic therapy.
Calquence delays disease progression as first-line treatment for mantle cell lymphoma
The addition of acalabrutinib to standard-of-care chemoimmunotherapy significantly extended PFS compared with standard therapy alone in a randomized study, according to press release the agent’s manufacturer.
Blood tests may predict which patients with lymphoma will have poor outcomes after CAR-T
Two blood biomarkers — pre-lymphodepletion C-reactive protein and ferritin — may help predict which patients with lymphoma are at risk for poor outcomes after chimeric antigen receptor T-cell therapy.
Dupilumab treatment for atopic dermatitis linked to cutaneous T-cell lymphoma development
A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.
Regimen improves OS in diffuse large B-cell lymphoma
The addition of glofitamab-gxbm to gemcitabine and oxaliplatin improved OS among patients with relapsed or refractory diffuse large B-cell lymphoma compared with rituximab, gemcitabine and oxaliplatin, according to the agent’s manufacturer.
Enalapril does not prevent chemotherapy-related heart damage in breast cancer, lymphoma
ATLANTA — Enalapril plus standard care was not superior to standard care alone for preventing cardiotoxicity in patients receiving treatment for breast cancer or lymphoma, according to new data from the PROACT trial.
‘We were shocked’: CAR-T rapidly reduces size of brain tumors in phase 1 trial
A novel bivalent-targeting, intrathecally delivered chimeric antigen receptor T-cell therapy decreased tumor size in patients with recurrent glioblastoma, according to results from a phase 1 study published in Nature Medicine.
Risk factors identified for secondary leukemia in patients who received CAR T cells
Researchers at Mayo Clinic have identified clinical factors associated with increased risk for developing myeloid neoplasms following chimeric antigen receptor T-cell therapy, according to data published in JAMA Oncology.
FDA grants accelerated approval to Brukinsa for advanced follicular lymphoma
The FDA granted accelerated approval to zanubrutinib in combination with obinutuzumab for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, according to a press release.